Quick Answer
Lineage Cell Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $14.56 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +53.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Lineage Cell Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 1.0%.
- Historical annual values: Fiscal year 2025: $14.56 million | Fiscal year 2024: $9.50 million | Fiscal year 2023: $8.95 million | Fiscal year 2022: $14.70 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: